Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept plus Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma
NCT04983407Phase 2Terminated
- Sponsor
- Aravive, Inc.
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of batiraxcept in pancreatic adenocarcinoma (PDAC), sponsored by Aravive, Inc.. Started Jul 2021; status: terminated.
02
Drugs
batiraxcept
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04983407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983407.